



UNIVERSITY OF LEEDS

This is a repository copy of *A Case of SLC29A3 Spectrum Disorder—Unresponsive to Multiple Immunomodulatory Therapies*.

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/101992/>

Article:

Mistry, A, Parry, D, Matthews, B et al. (3 more authors) (2016) A Case of SLC29A3 Spectrum Disorder—Unresponsive to Multiple Immunomodulatory Therapies. *Journal of Clinical Immunology*, 36 (5). pp. 429-433. ISSN 0271-9142

<https://doi.org/10.1007/s10875-016-0301-6>

Reuse

Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

[Click here to view linked References](#)

A case of SLC29A3 spectrum disorder - unresponsive to multiple immunomodulatory therapies

Anoop Mistry¹, David Parry², Bipin Matthews³, Philip Laws⁴, Mark Goodfield⁴, Sinisa Savic^{1,5*}

¹Department of Clinical Immunology and Allergy, St James's University Hospital, Leeds, UK;

²Centre for Genomic & Experimental Medicine, Institute of Genetics & Molecular Medicine, University of Edinburgh, UK

³Department of Histopathology, Hull Royal Infirmary, Hull, UK

⁴Department of Dermatology, Chapel Allerton Hospital, Leeds, UK

⁵National Institute for Health Research–Leeds Musculoskeletal Biomedical Research Unit (NIHR-LMBRU) and Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), Wellcome Trust Brenner Building, St James's University Hospital, Beckett Street, Leeds, UK

* Corresponding author: Sinisa Savic MD, PhD Department of Clinical Immunology and Allergy, National Institute for Health Research–Leeds Musculoskeletal Biomedical Research Unit (NIHR-LMBRU) and Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), Wellcome Trust Brenner Building, St James's University Hospital, Beckett Street, Leeds, UK Email: s.savic@leeds.ac.uk, Telephone: +441132065567, Fax: +441132067250

Abbreviations

- 1 SLE- Systemic lupus erythematosus
- 2
- 3 RDD- Rosai-Dorfmann disease
- 4
- 5 FHC- Faisalabad histiocytosis
- 6
- 7 SHML- Sinus histiocytosis with massive lymphadenopathy
- 8
- 9 PHID- Pigmented hypertrichosis with insulin-dependent diabetes mellitus syndrome
- 10
- 11 CRP- C-reactive Protein
- 12
- 13 DMARD- Disease Modifying Anti-Rheumatic Drug

Key Words

- 14 SLC29A3 spectrum disorder
- 15
- 16 H syndrome,
- 17
- 18 SLC29A3,
- 19
- 20 Rosai-Dorfmann disease,
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65

1 To the editor,
2
3

4 Histiocytosis are a group of rare disorders caused by an excessive number of histiocytes which
5 phagocytose other cells. Their pathophysiology remains uncertain and their treatment non-specific.
6 Rosai-Dorfmann disease (RDD) is a particular form of histiocytosis which presents with massive
7 lymphadenopathy, it can be familial or occur sporadically. The histiocytosis-lymphadenopathy plus
8 syndrome comprises features of four histiocytic disorders (#OMM 602782):
9

- 10 1. Faisalabad histiocytosis (FHC)
 - 11 2. Sinus histiocytosis with massive lymphadenopathy (SHML), also known as familial RDD
 - 12 3. H syndrome
 - 13 4. Pigmented hypertrichosis with insulin-dependent diabetes mellitus syndrome (PHID)
- 14
15
16
17
18
19
20

21 These conditions were once thought to be separate disorders; however in light of the overlapping
22 features and shared genetic cause, they are now considered to be part of the same disease
23 spectrum. They are all caused by homozygous or compound heterozygous mutation in the *SLC29A3*
24 gene on chromosome 10q22, hence they are also called SLC29A3 spectrum disorders (1-6). Their
25 clinical features are summarised in Figure 1.
26
27
28
29

30 The *SLC29A3* gene encodes equilibrative nucleoside transporter 3(ENT3). ENT3 belongs to a family
31 of nucleoside transport proteins which play key roles in nucleoside metabolism. ENT3 is ubiquitously
32 expressed, particularly on endosomal and mitochondrial membranes (7). *SLC29A3* mutations typically
33 cause altered stability of the ENT protein (8). SLC29A3-null mice develop lysosomal accumulation of
34 nucleotides and altered macrophage function (9), which provides a molecular basis for some clinical
35 aspects of the SLC29A3 spectrum disorders, however it does not explain the entire phenotype.
36
37
38
39
40

41 Information on the gross clinical phenotype of SLC29A3 spectrum disorders has been described.
42 However information on the immunological abnormalities and management of these disorders
43 remains sparse. We present the case of a 21-year-old female patient with SLC29A3 spectrum
44 disorder whose symptoms have been refractory to a number of immunomodulatory therapies.
45
46
47

48 The patient is from a consanguineous marriage (her parents are first cousins). She initially presented
49 at the age of two with a self-limiting sharply demarcated telangiectatic rash. Subsequently, she
50 developed a number of ill-defined problems including dactylitis, arthralgia and debilitating fatigue. In
51 her early teenage years, she was managed with a working diagnosis of Systemic Lupus
52 Erythematosus (SLE) in view of her troublesome rash; progressive alopecia, microscopic haematuria
53 and a positive anti-double stranded DNA antibody titre. The diagnosis of SLE did not however unify
54 her other symptoms and clinical features (Table 1). This included RDD which initially presented at the
55
56
57
58
59
60
61
62
63
64
65

1 age of 9 with a large painless right mandibular mass. Excision of the mass showed massively
2 enlarged lymph nodes which had features in keeping with RDD on microscopic examination (Fig.2).
3

4 Her most troublesome symptoms were cutaneous. At the age of 11 she developed crusted purple
5 plaques affecting the pinnae of her ears, forearms and shins. The gross clinical appearance of the
6 rash was consistent with discoid lupus, however biopsies confirmed lichen planus, with no suggestion
7 of SLE. More recently the patient has developed a more diffuse rash consisting of widespread
8 nodules, histopathology showed a mixed infiltrate of enlarged histiocytes containing phagocytosed
9 lymphocytes. The histiocytes show a CD68+,CD163+,S100+,CD1a- immunophenotype in keeping
10 with Rosai-Dorfmann disease.
11
12
13
14
15

16 Blood work has invariably shown a balanced lymphopenia affecting T and B cells with normal
17 numbers of NK cells. Further B cell analysis showed reduced class-switched memory compartment.
18 Phytohaemagglutinin induced T cell proliferation was normal (Table 2). The patient initially had a
19 polyclonal gammaglobulinaemia, she subsequently developed an IgG kappa paraproteinaemia
20 (Figure 3) as well as a persistently raised C-reactive protein (CRP) between 30-50mg/l.
21
22
23
24

25 In view of her lymphadenopathy, and autoimmune features, a diagnosis of autoimmune
26 lymphoproliferative syndrome (ALPS) was also considered. However, further studies including
27 functional apoptosis assays, analysis of double negative T cells, serum levels of B12 vitamin, soluble
28 Fas ligand and Intreleukin-10 were all normal. A diagnosis of autoimmune polyendocrine syndrome
29 type 1 was another diagnosis under consideration, but genetic test for *AIRE* gene mutations was
30 negative. Her lymphadenopathy, hyperpigmentation and pedigree suggested Gaucher's disease.
31 However, normal glucocerebrosidase tests excluded this lysosomal disorder.
32
33
34
35

36 The diagnosis of a SLC29A3 spectrum disorder was made with the aid of whole exome sequencing.
37 She was found to have homozygous mutation in the splice donor site in the second intron of
38 *SLC29A3* (NM_018344.5:c.300+1G>A). Considering her clinical features and the fact that this variant
39 has been previously described in a family with FHC [2], it was concluded that this mutation is the most
40 likely cause of her condition.
41
42
43
44

45 Multiple therapies were trialed to manage the patient's cutaneous and musculoskeletal symptoms.
46 She had a course of hydroxychloroquine, ciclosporin, methotrexate, thalidomide and mycophenolate
47 for her skin. There was intial response to thalidomide and her lichen planus cleared after 15 months of
48 treatment. However two further courses of thalidomide were ineffective for recurrence of lichen
49 planus. She had a trial of tocilizumab and rituximab for inflammatory musculoskeletal symptoms.
50 Tocilizumab was effective in normalizing the CRP but this was not associated with clinical
51 improvement. Similarly Rituximab seemed to reduce the polyclonal increase of IgG to normal levels
52 from a peak of 28.4 g/L, but again there was no improvement clinically. In addition to these therapies
53 the patient also received multiple courses of oral steroids which had a modest effect. Intra-articular
54 steroid injections have provided some symptomatic relief.
55
56
57
58
59
60
61
62
63
64
65

1 Our case describes the abnormal immunological findings that may be present in SLC29A3 spectrum
2 disorders. This has rarely been explicitly reported despite the observation that autoimmune conditions
3 such as haemolytic anaemia [3,4] and pancytopenia [5] may be associated with the syndrome. To
4 date we could only find three other cases which characterized the immune system in affected
5 patients. Melki et al reported a patient with a confirmed mutation in the *SLC29A3* gene and clinical
6 features of H syndrome which became apparent in the first year of life [10]. He was found to have
7 raised IgG and IgA levels. Notably, the patient had intermittent febrile episodes coinciding with raised
8 inflammatory markers, a feature specific to the case. Severe systemic inflammation was also reported
9 in a case of PHID. Here a 12 year old girl presented scleroderma-like changes, cardiomyopathy,
10 hepatosplenomegaly, and raised erythrocyte sedimentation rate and CRP. Although she was found to
11 have significantly elevated serum amyloid A, no systemic amyloid deposits were observed on a
12 whole-body serum amyloid P scintigraphy scan [11]. More recently, Fujita et al. reported a male
13 patient with characteristics of H syndrome in addition to Raynaud's phenomenon and retroperitoneal
14 fibrosis [12]. He was found to have raised inflammatory markers. Notably, this patient had a novel
15 mutation in the *SLC29A3* gene, suggesting that different mutations within the gene may lead to
16 variant phenotypes. Most importantly these reports suggest that SLC29A3 spectrum disorder patients
17 have abnormal immunological findings which may have gone un-investigated in previous case
18 reports.

19
20
21
22
23
24
25
26
27
28
29
30
31 Various treatments having being trialled with patients with phenotypic characteristics of SLC29A3
32 spectrum disorders including methotrexate, 6- mercaptopurine and interferon alpha. At best these
33 therapies had a modest benefit. Inevitably, the information gleaned from such case reports must be
34 interpreted with caution, as the patients were not all genotyped. Ciclosporin and cyclophosphamide
35 therapy however have been tested in a patient with a confirmed *SLC29A3* mutation;
36 cyclophosphamide was reported to have had no effect, while ciclosporin apparently led to an
37 improvement [13]. In Melki's case colchicine, anakinra, canakinumab and adalimumab were
38 sequentially tested with no clinical response; non-steroidal anti-inflammatory drugs however did
39 reduce the frequency of pyrexial episodes [10]. Similarly anakinra and anti-TNF blockade were also
40 not effective in the patient with cardiomyopathy, hepatosplenomegaly and raised SAA [11]. In Fujita's
41 patient prednisolone had some effect in treating skin lesions [12].

42
43
44
45
46
47
48 Our case adds to this current body of literature by highlighting that this condition seems to be
49 associated with chronic inflammatory response, paraproteinaemia and a clinically diverse range of
50 features. Most importantly immunomodulatory treatments, including biological agents targeting the
51 pro-inflammatory cytokines, do not appear to have a significant effect on this condition. Considering
52 that expression of ENT3 is not limited to the hematopoietic stem cells, and that the clinical phenotype
53 is probably not entirely due to the inherent abnormalities of the immune system, it is questionable that
54 more radical procedures, such as bone marrow transplant, would be successful for treatment of these
55 disorders.

Funding

SS is supported by grants from Leeds Institute of Rheumatic and Musculoskeletal Medicine and Leeds Teaching Hospitals Charitable Foundation (9/R21/14-07)

This work was supported by a Sir Jules Thorn Award for Biomedical Research (JTA/09 to C.A.J.)

Conflict of Interest

The authors have no relevant conflicts of interest.

References

1. Molho-Pessach V, Ramot Y, Camille F, Doviner V, Babay S, Juan Luis S, et al. H syndrome: The first 79 patients. *J Am Acad Dermatol* 2013; 70:80-88.
2. Morgan NV, Morris MR, Cangul H, Gleeson D, Straatman-Iwanowska A, Davies N, et al. Mutations in *SLC29A3*, Encoding an Equilibrative Nucleoside Transporter ENT3, Cause a Familial Histiocytosis Syndrome (Faisalabad Histiocytosis) and Familial Rosai-Dorfman Disease. *PLoS Genet.* 2010;6:e1000833
3. Doviner V, Maly A, Ne'eman, Qawasmi R, Amar S, Sultan M, et al. H syndrome: recently defined genodermatosis with distinct histologic features: a morphologic, histochemical, immunohistochemical and ultrastructural study of ten cases. *Am J Dermatopathol* 2010; 32: 118-28.
4. Avitan-Hersh E, Mandel H, Indelman M, Bar-Joseph G, Zlotogorski A, Bergman R. A case of H syndrome immunophenotype similarities of Rosai Dorfman disease. *Am J Dermatopath* 2011; 33: 47-53.
5. Priya TP, Philip N, Molho-Pessach V, Busa T, Dalal A, Zlotogorski A. H syndrome: novel and recurrent mutations in *SLC29A3*. *Br J Dermatol* 2010; 162: 1132-4.
6. Cliffe ST, Kramer JM, Hussain K, Robben JH, de Jong EK, de Brouwer AP, Nibbeling E, Kamsteeg EJ, Wong M, Prendiville J, James C, Padidela R, Becknell C, van Bokhoven H, Deen PM, Hennekam RC, Lindeman R, Schenck A, Roscioli T, Buckley MF. *SLC29A3* gene is mutated in pigmented hypertrichosis with insulin-dependent diabetes mellitus syndrome and interacts with the insulin signaling pathway. *Hum Mol Genet.* 2009;18:2257-65.
7. Young JD, Yao SY, Baldwin JM, Cass CE, Baldwin SA. The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29. *Mol Aspects Med.* 2013;34:529-547
8. Kang, N., Jun, A.H., Bhutia, Y.D., Kannan, N., Unadkat, J.D., Govindarajan, R., 2010. Human equilibrative nucleoside transporter-3 (hENT3) spectrum disorder mutations impair nucleoside transport, protein localization, and stability. *J. Biol. Chem.* 285, 28343–28352.
9. Hsu, C.L., Lin, W., Seshasayee, D., Chen, Y.H., Ding, X., Lin, Z., Suto, E., Huang, Z., Lee, W.P., Park, H., Xu, M., Sun, M., Rangell, L., Lutman, J.L., Ulufatu, S., Stefanich, E., Chalouni, C., Sagolla, M., Diehl, L., Fielder, P., Dean, B., Balazs, M., Martin, F., 2011. Equilibrative nucleoside transporter 3 deficiency perturbs lysosome function and macrophage homeostasis. *Science* 335, 89–92.
10. Melki I, Lambot K, Jonard L, Couloigner V, Quartier P, Neven B, et al. Mutation in the *SLC29A3* gene: a new cause of a monogenic autoinflammatory condition. *Pediatrics* 2013; 131: e1308-13.
11. Senniappan S, Hughes M, Shah P, Shah V, Kaski JP, Brogan P, Hussain KJ. Pigmentary hypertrichosis and non-autoimmune insulin-dependent diabetes mellitus (PHID) syndrome is associated with severe chronic inflammation and cardiomyopathy, and represents a new monogenic autoinflammatory syndrome. *Pediatr Endocrinol Metab.* 2013;26:877-82

- 1
2
3
4
5
6
7
8
9
12. Fujita E, Komine M, Tsuda H, Adachi A, Murata S, Kamata Y. Case of H syndrome with massive skin involvement, retroperitoneal fibrosis and Raynaud's phenomenon with a novel mutation in the SLC29A3 gene. *The Journal of Dermatology* 2015, 42: 1169–1171
 13. De Jesus J, Imane Z, Senee V, Romero S, Guillauseau PJ, Balafrej et al. SLC29A3 mutation in a patient with syndromic diabetes with features of pigmented hypertrichotic dermatosis with insulin-dependent diabetes, H syndrome and Faisalabad histiocytosis. *Diabetes Metabol* 2013; 39: 281-5.


10
11
12
13
14
15
16
17
18
19


Figure 1. Clinical features of SLC29A3 spectrum disorders.

20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 2. (A) Haematoxylin Eosin stain x25 magnification: lymph node showing capsular fibrosis, reactive germinal centres and dilated sinuses filled with large histiocytes.
(B) Haematoxylin Eosin stain x 400 magnification: lymph node showing enlarged histiocytes (marked with) containing central nuclei and abundant pale cytoplasm with lymphophagocytosis.

Figure 3. IgG (red), IgA (green) and IgM (black) levels in g/l. *IgG Kappa monoclonal band was detectable by serum electrophoresis, however the paraprotein levels were too low for quantification








Table 1. Clinical features present in case patient

Previously described in association with H syndrome	Features specific to this case
<ul style="list-style-type: none">• Sensorineural deafness• Interphalangeal joint deformities• Pes Planus• Short stature (0.4th centile)• Arthralgia• Myalgia• Pancreatic insufficiency• Malabsorption• Diabetes Mellitus• Skeletal abnormalities• Hyperpigmentation• Rosai-Dorfmann disease	<ul style="list-style-type: none">• Proximal myopathy• Anti-double stranded DNA positive• Antinuclear antibody positive• Lichen planus• Alopecia totalis• Lymphopenia

Table 2 Lymphocyte studies

Tests	2006	2009	2010	2011	Normal ranges
CD3+ Lymphocytes (cells/ μ l)	302	484	411	501	700-2100 cells/ μ l
CD4+ T cells (cells/ μ l)	201	370	305	400	300-1400 cells/ μ l
CD8+ T cells (cells/ μ l)	73	106	94	95	200-900 cells/ μ l
NK cells CD56+ (cells/ μ l)	105	108	149	156	90-600 cells/ μ l
B cells (CD19+) cells/ μ l	72	196	115	88	100-500 cells/ μ l
ratio	2.75	3.49	3.24	4.21	1.07-1.87
Marginal zone B cells CD19+ CD27+ IgD+ (% of CD19+)			0.84%		0.5-8%*
Class switched memory B cells CD19+ CD27+ IgD- (% of CD19+)			2.20%		3-18%*
PHA induced lymphocyte proliferation			Normal		N/A

PHA: phytohaemagglutinin;

* Schatorje EJ, et al. Age-matched reference values for B-lymphocyte subpopulations and CVID classifications in children. Scand J Immunol 2011;74:502-10

A case of **SLC29A3 spectrum disorder** - unresponsive to multiple immunomodulatory therapies

Anoop Mistry¹, David Parry², Bipin Matthews³, Philip Laws⁴, Mark Goodfield⁴, Sinisa Savic^{1,5*}

¹Department of Clinical Immunology and Allergy, St James's University Hospital, Leeds, UK;

²Centre for Genomic & Experimental Medicine, Institute of Genetics & Molecular Medicine, University of Edinburgh, UK

³Department of Histopathology, Hull Royal Infirmary, Hull, UK

⁴Department of Dermatology, Chapel Allerton Hospital, Leeds, UK

⁵National Institute for Health Research–Leeds Musculoskeletal Biomedical Research Unit (NIHR-LMBRU) and Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), Wellcome Trust Brenner Building, St James's University Hospital, Beckett Street, Leeds, UK

* Corresponding author: Sinisa Savic MD, PhD Department of Clinical Immunology and Allergy, National Institute for Health Research–Leeds Musculoskeletal Biomedical Research Unit (NIHR-LMBRU) and Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), Wellcome Trust Brenner Building, St James's University Hospital, Beckett Street, Leeds, UK Email: s.savic@leeds.ac.uk, Telephone: +441132065567, Fax: +441132067250

Abbreviations

SLE- Systemic lupus erythematosus

RDD- Rosai-Dorfmann disease

FHC- Faisalabad histiocytosis

SHML- Sinus histiocytosis with massive lymphadenopathy

PHID- Pigmented hypertrichosis with insulin-dependent diabetes mellitus syndrome

CRP- C-reactive Protein

DMARD- Disease Modifying Anti-Rheumatic Drug

Key Words

SLC29A3 spectrum disorder

H syndrome,

SLC29A3,

Rosai-Dorfmann disease,

To the editor,

Histiocytosis are a group of rare disorders caused by an excessive number of histiocytes which phagocytose other cells. Their pathophysiology remains uncertain and their treatment non-specific. Rosai-Dorfmann disease (RDD) is a particular form of histiocytosis which presents with massive lymphadenopathy, it can be familial or occur sporadically. The histiocytosis-lymphadenopathy plus syndrome comprises features of four histiocytic disorders (#OMM 602782):

1. Faisalabad histiocytosis (FHC)
2. Sinus histiocytosis with massive lymphadenopathy (SHML), also known as familial RDD
3. H syndrome
4. Pigmented hypertrichosis with insulin-dependent diabetes mellitus syndrome (PHID)

These conditions were once thought to be separate disorders; however in light of the overlapping features and shared genetic cause, they are now considered to be part of the same disease spectrum. They are all caused by homozygous or compound heterozygous mutation in the *SLC29A3* gene on chromosome 10q22, hence they are also called SLC29A3 spectrum disorders (1-6). Their clinical features are summarised in Figure 1.

The *SLC29A3* gene encodes equilibrative nucleoside transporter 3(ENT3). ENT3 belongs to a family of nucleoside transport proteins which play key roles in nucleoside metabolism. ENT3 is ubiquitously expressed, particularly on endosomal and mitochondrial membranes (7). *SLC29A3* mutations typically cause altered stability of the ENT protein (8). SLC29A3-null mice develop lysosomal accumulation of nucleotides and altered macrophage function (9), which provides a molecular basis for some clinical aspects of the SLC29A3 spectrum disorders, however it does not explain the entire phenotype.

Information on the gross clinical phenotype of SLC29A3 spectrum disorders has been described. However information on the immunological abnormalities and management of these disorders remains sparse. We present the case of a 21-year-old female patient with SLC29A3 spectrum disorder whose symptoms have been refractory to a number of immunomodulatory therapies.

The patient is from a consanguineous marriage (her parents are first cousins). She initially presented at the age of two with a self-limiting sharply demarcated telangiectatic rash. Subsequently, she developed a number of ill-defined problems including dactylitis, arthralgia and debilitating fatigue. In her early teenage years, she was managed with a working diagnosis of Systemic Lupus Erythematosus (SLE) in view of her troublesome rash; progressive alopecia, microscopic haematuria and a positive anti-double stranded DNA antibody titre. The diagnosis of SLE did not however unify her other symptoms and clinical features (Table 1). This included RDD which initially presented at the

age of 9 with a large painless right mandibular mass. Excision of the mass showed massively enlarged lymph nodes which had features in keeping with RDD on microscopic examination (Fig.2).

Her most troublesome symptoms were cutaneous. At the age of 11 she developed crusted purple plaques affecting the pinnae of her ears, forearms and shins. The gross clinical appearance of the rash was consistent with discoid lupus, however biopsies confirmed lichen planus, with no suggestion of SLE. More recently the patient has developed a more diffuse rash consisting of widespread nodules, histopathology showed a mixed infiltrate of enlarged histiocytes containing phagocytosed lymphocytes. The histiocytes show a CD68+,CD163+,S100+,CD1a- immunophenotype in keeping with Rosai-Dorfmann disease.

Blood work has invariably shown a balanced lymphopenia affecting T and B cells with normal numbers of NK cells. Further B cell analysis showed reduced class-switched memory compartment. Phytohaemagglutinin induced T cell proliferation was normal (Table 2). The patient initially had a polyclonal gammaglobulinaemia, she subsequently developed an IgG kappa paraproteinaemia (Figure 3) as well as a persistently raised C-reactive protein (CRP) between 30-50mg/l.

In view of her lymphadenopathy, and autoimmune features, a diagnosis of autoimmune lymphoproliferative syndrome (ALPS) was also considered. However, further studies including functional apoptosis assays, analysis of double negative T cells, serum levels of B12 vitamin, soluble Fas ligand and Interleukin-10 were all normal. A diagnosis of autoimmune polyendocrine syndrome type 1 was another diagnosis under consideration, but genetic test for *AIRE* gene mutations was negative. Her lymphadenopathy, hyperpigmentation and pedigree suggested Gaucher's disease. However, normal glucocerebrosidase tests excluded this lysosomal disorder.

The diagnosis of a *SLC29A3* spectrum disorder was made with the aid of whole exome sequencing. She was found to have homozygous mutation in the splice donor site in the second intron of *SLC29A3* (NM_018344.5:c.300+1G>A). Considering her clinical features and the fact that this variant has been previously described in a family with FHC [2], it was concluded that this mutation is the most likely cause of her condition.

Multiple therapies were trialed to manage the patient's cutaneous and musculoskeletal symptoms. She had a course of hydroxychloroquine, ciclosporin, methotrexate, thalidomide and mycophenolate for her skin. There was initial response to thalidomide and her lichen planus cleared after 15 months of treatment. However two further courses of thalidomide were ineffective for recurrence of lichen planus. She had a trial of tocilizumab and rituximab for inflammatory musculoskeletal symptoms. Tocilizumab was effective in normalizing the CRP but this was not associated with clinical improvement. Similarly Rituximab seemed to reduce the polyclonal increase of IgG to normal levels from a peak of 28.4 g/L, but again there was no improvement clinically. In addition to these therapies the patient also received multiple courses of oral steroids which had a modest effect. Intra-articular steroid injections have provided some symptomatic relief.

Our case describes the abnormal immunological findings that may be present in **SLC29A3 spectrum disorders**. This has rarely been explicitly reported despite the **observation** that autoimmune conditions such as haemolytic anaemia [3,4] and pancytopenia [5] may be associated with the syndrome. To date we could only find three other cases which characterized the immune system in affected patients. Melki et al reported a patient with a confirmed mutation in the *SLC29A3* gene and clinical features of H syndrome which became apparent in the first year of life [10]. He was found to have raised IgG and IgA levels. Notably, the patient had intermittent febrile episodes coinciding with raised inflammatory markers, a feature specific to the case. **Severe systemic inflammation was also reported in a case of PHID. Here a 12 year old girl presented scleroderma-like changes, cardiomyopathy, hepatosplenomegaly, and raised erythrocyte sedimentation rate and CRP. Although she was found to have significantly elevated serum amyloid A, no systemic amyloid deposits were observed on a whole-body serum amyloid P scintigraphy scan** [11]. More recently, Fujita et al. reported a male patient with characteristics of H syndrome in addition to Raynaud's phenomenon and retroperitoneal fibrosis [12]. He was found to have raised inflammatory markers. Notably, this patient had a novel mutation in the *SLC29A3* gene, suggesting that different mutations within the gene may lead to variant phenotypes. Most importantly these reports suggest that **SLC29A3 spectrum disorder** patients have abnormal **immunological findings** which may have gone un-investigated in previous case reports.

Various treatments having being trialled with patients with phenotypic characteristics of **SLC29A3 spectrum disorders** including methotrexate, 6- mercaptopurine and interferon alpha. At best these therapies had a modest benefit. Inevitably, the information gleaned from such case reports must be interpreted with caution, as the patients were not all genotyped. Ciclosporin and cyclophosphamide therapy however have been tested in a patient with a confirmed *SLC29A3* mutation; cyclophosphamide was reported to have had no effect, while ciclosporin apparently led to an improvement [13]. In Melki's case colchicine, anakinra, canakinumab and adalimumab were sequentially tested with no clinical response; non-steroidal anti-inflammatory drugs however did reduce the frequency of pyrexial episodes [10]. **Similarly anakinra and anti-TNF blockade were also not effective in the patient with cardiomyopathy, hepatosplenomegaly and raised SAA** [11]. In Fujita's patient prednisolone had some effect in treating skin lesions [12].

Our case adds to this current body of literature by highlighting that this condition seems to be associated with chronic **inflammatory response**, paraproteinaemia and a clinically diverse range of features. Most importantly immunomodulatory treatments, **including biological agents targeting the pro-inflammatory cytokines, do not appear to have a significant effect on this condition. Considering that expression of ENT3 is not limited to the hematopoietic stem cells, and that the clinical phenotype is probably not entirely due to the inherent abnormalities of the immune system, it is questionable that more radical procedures, such as bone marrow transplant, would be successful for treatment of these disorders.**

Funding

SS is supported by grants from Leeds Institute of Rheumatic and Musculoskeletal Medicine and Leeds Teaching Hospitals Charitable Foundation (9/R21/14-07)

This work was supported by a Sir Jules Thorn Award for Biomedical Research (JTA/09 to C.A.J.)

Conflict of Interest

The authors have no relevant conflicts of interest.

References

1. Molho-Pessach V, Ramot Y, Camille F, Doviner V, Babay S, Juan Luis S, et al. H syndrome: The first 79 patients. *J Am Acad Dermatol* 2013; 70:80-88.
2. Morgan NV, Morris MR, Cangul H, Gleeson D, Straatman-Iwanowska A, Davies N, et al. Mutations in *SLC29A3*, Encoding an Equilibrative Nucleoside Transporter ENT3, Cause a Familial Histiocytosis Syndrome (Faisalabad Histiocytosis) and Familial Rosai-Dorfman Disease. *PLoS Genet.* 2010;6:e1000833
3. Doviner V, Maly A, Ne'eman, Qawasmi R, Amar S, Sultan M, et al. H syndrome: recently defined genodermatosis with distinct histologic features: a morphologic, histochemical, immunohistochemical and ultrastructural study of ten cases. *Am J Dermatopathol* 2010; 32: 118-28.
4. Avitan-Hersh E, Mandel H, Indelman M, Bar-Joseph G, Zlotogorski A, Bergman R. A case of H syndrome immunophenotype similarities of Rosai Dorfman disease. *Am J Dermatopath* 2011; 33: 47-53.
5. Priya TP, Philip N, Molho-Pessach V, Busa T, Dalal A, Zlotogorski A. H syndrome: novel and recurrent mutations in *SLC29A3*. *Br J Dermatol* 2010; 162: 1132-4.
6. Cliffe ST, Kramer JM, Hussain K, Robben JH, de Jong EK, de Brouwer AP, Nibbeling E, Kamsteeg EJ, Wong M, Prendiville J, James C, Padidela R, Becknell C, van Bokhoven H, Deen PM, Hennekam RC, Lindeman R, Schenck A, Roscioli T, Buckley MF. *SLC29A3* gene is mutated in pigmented hypertrichosis with insulin-dependent diabetes mellitus syndrome and interacts with the insulin signaling pathway. *Hum Mol Genet.* 2009;18:2257-65.
7. Young JD, Yao SY, Baldwin JM, Cass CE, Baldwin SA. 47The human concentrative and equilibrative nucleoside transporter families, *SLC28* and *SLC29*. *Mol Aspects Med.* 2013;34:529-547
8. Kang, N., Jun, A.H., Bhutia, Y.D., Kannan, N., Unadkat, J.D., Govindarajan, R., 2010. Human equilibrative nucleoside transporter-3 (hENT3) spectrum disorder mutations impair nucleoside transport, protein localization, and stability. *J. Biol. Chem.* 285, 28343–28352.
9. Hsu, C.L., Lin, W., Seshasayee, D., Chen, Y.H., Ding, X., Lin, Z., Suto, E., Huang, Z., Lee, W.P., Park, H., Xu, M., Sun, M., Rangell, L., Lutman, J.L., Ulufatu, S., Stefanich, E., Chalouni, C., Sagolla, M., Diehl, L., Fielder, P., Dean, B., Balazs, M., Martin, F., 2011. Equilibrative nucleoside transporter 3 deficiency perturbs lysosome function and macrophage homeostasis. *Science* 335, 89–92.
10. Melki I, Lambot K, Jonard L, Couloigner V, Quartier P, Neven B, et al. Mutation in the *SLC29A3* gene: a new cause of a monogenic autoinflammatory condition. *Pediatrics* 2013; 131: e1308-13.
11. Senniappan S, Hughes M, Shah P, Shah V, Kaski JP, Brogan P, Hussain KJ. Pigmentary hypertrichosis and non-autoimmune insulin-dependent diabetes mellitus (PHID) syndrome is associated with severe chronic inflammation and cardiomyopathy, and represents a new monogenic autoinflammatory syndrome. *Pediatr Endocrinol Metab.* 2013;26:877-82


12. Fujita E, Komine M, Tsuda H, Adachi A, Murata S, Kamata Y. Case of H syndrome with massive skin involvement, retroperitoneal fibrosis and Raynaud's phenomenon with a novel mutation in the SLC29A3 gene. *The Journal of Dermatology* 2015, 42: 1169–1171
13. De Jesus J, Imane Z, Senee V, Romero S, Guillauseau PJ, Balafrej et al. SLC29A3 mutation in a patient with syndromic diabetes with features of pigmented hypertrichotic dermatosis with insulin-dependent diabetes, H syndrome and Faisalabad histiocytosis. *Diabetes Metabol* 2013; 39: 281-5.

Figure 1. Clinical features of SLC29A3 spectrum disorders.

Figure 2. (A) Haematoxylin Eosin stain x25 magnification: lymph node showing capsular fibrosis, reactive germinal centres and dilated sinuses filled with large histiocytes.

(B) Haematoxylin Eosin stain x 400 magnification: lymph node showing enlarged histiocytes (marked with) containing central nuclei and abundant pale cytoplasm with lymphophagocytosis.

Figure 3. IgG (red), IgA (green) and IgM (black) levels in g/l. *IgG Kappa monoclonal band was detectable by serum electrophoresis, however the paraprotein levels were too low for quantification



Conflict of Interest Disclosure Form

It is the policy of *Journal of Clinical Immunology* to ensure balance, independence, objectivity, and scientific rigor in the Journal. All authors are expected to disclose to the readers any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the article. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers or other corporation whose products or services may be related to the subject matter of the article or who have sponsored the study.

The intent of the policy is not to prevent authors with potential conflict of interest from publication. It is merely intended that any potential conflict should be identified openly so that the readers may form their own judgements about the article with the full disclosure of the facts. It is for the readers to determine whether the authors' outside interest may reflect a possible bias in either the exposition of the conclusions presented.

The corresponding author will complete and submit this form on behalf of all authors listed below.

Article Title A case of H Syndrome - unresponsive to multiple immunomodulatory therapies

Authors Anoop Mistry, David Parry, Bipin Matthews, Philip Laws, Mark Goodfield, Sinisa Savic

MS Id. No. _____

Please note that a conflict of interest statement is published with each paper.

I certify that there is no actual or potential conflict of interest in relation to this article. If any conflict exists, please define hereafter:

Conflict (if none, "None" or describe financial interest/arrangement with one or more organizations that could be perceived as a real or apparent conflict of interest in the context on the subject of this article):

None

Name Sinisa Savic

Signature *Sinisa Savic* Date 24 Feb 2016

Please scan the completed and signed form and then submit it as an electronic file along with your manuscript. No manuscripts will be accepted for review without this form.



<http://www.springer.com/journal/10875>

Journal of Clinical Immunology
Editor-in-Chief: Vincent Bonagura

ISSN: 0271-9142 (print version)
ISSN: 1573-2592 (electronic version)
Journal no. 10875
Springer



<http://www.springer.com/journal/10875>

Journal of Clinical Immunology

Editor-in-Chief: Bonagura, V. – Deputy Editor-in-Chief:

Casanova, J.-L. – Managing Editor: Rosenthal, D.

ISSN: 0271-9142 (print version)

ISSN: 1573-2592 (electronic version)

Journal no. 10875